1 00:00:00,240 --> 00:00:00,560 Foreign. 2 00:00:07,600 --> 00:00:11,040 Welcome back to Translating Proteomics. On this episode, Andreas 3 00:00:11,040 --> 00:00:14,200 and I are excited to answer questions submitted by members of 4 00:00:14,200 --> 00:00:18,920 the Translating Proteomics community. Before we begin, I'd really 5 00:00:18,920 --> 00:00:22,160 like to extend a heartfelt thanks to everyone who submitted 6 00:00:22,160 --> 00:00:25,760 questions over email on YouTube, on Reddit and elsewhere. 7 00:00:26,860 --> 00:00:31,260 It is just fantastic to see so many people engaged with and excited 8 00:00:31,260 --> 00:00:34,820 about the future of proteomics. We'd also like to acknowledge 9 00:00:34,820 --> 00:00:38,220 that we got a bunch of really insightful questions about Nautilus 10 00:00:38,220 --> 00:00:42,540 technology. We only have a short amount of time today, so we're 11 00:00:42,540 --> 00:00:45,980 going to answer one Nautilus focused question at the end of the 12 00:00:45,980 --> 00:00:50,180 episode and three broader, more general proteomics questions 13 00:00:50,180 --> 00:00:55,260 before that. If you're hungry for more information about our technology 14 00:00:55,260 --> 00:00:59,430 at Nautilus, we no worries. We'll post a video on our YouTube 15 00:00:59,430 --> 00:01:03,630 channel shortly where I'll answer many of your Nautilus technology 16 00:01:03,790 --> 00:01:07,470 focused questions. In the meantime, I recommend checking out 17 00:01:07,470 --> 00:01:11,030 our recently posted Bioarchive Preprint, our blog and the Resources 18 00:01:11,030 --> 00:01:14,870 page on our website where you can learn a ton about the Nautilus 19 00:01:14,870 --> 00:01:18,790 proteome analysis platform and its technical capabilities. You can 20 00:01:18,790 --> 00:01:21,430 find these links to all these resources in the description of this 21 00:01:21,430 --> 00:01:25,050 episode. With that, Andreas, what's our first question? 22 00:01:26,090 --> 00:01:30,850 Well, let's get things started with a question from Bharat Kumar 23 00:01:30,850 --> 00:01:35,130 91. He submitted the following questions as a comment on our YouTube 24 00:01:35,130 --> 00:01:40,490 video channel and he is asking are we missing things in plasma proteomics 25 00:01:40,490 --> 00:01:44,450 because we keep searching for needles in the haystack and ignoring 26 00:01:44,450 --> 00:01:49,090 the haystack? For instance, are there important insights in the 27 00:01:49,090 --> 00:01:53,410 higher bound proteins like albumin? Do we establish absolute 28 00:01:53,410 --> 00:01:57,530 plasma protein quantities with reference intervals across dynamic 29 00:01:57,530 --> 00:02:01,530 range of the plasma proteome to help us move from relative trends 30 00:02:01,530 --> 00:02:05,410 to absolute numbers? Now, I believe you have a lot of comments 31 00:02:05,490 --> 00:02:08,210 and insights in this field, so take it away. 32 00:02:09,010 --> 00:02:14,090 Absolutely. I think certainly my academic lab has studied biomarkers 33 00:02:14,090 --> 00:02:18,280 and the plasma proteome for a long time and so I do have a of lot 34 00:02:18,510 --> 00:02:22,910 lot of thoughts just to try and organize them. I'll first start 35 00:02:23,150 --> 00:02:27,310 with just high abundance proteins. It's certainly true that 36 00:02:27,310 --> 00:02:31,430 a large number of proteomics workflows, the first thing that's 37 00:02:31,430 --> 00:02:36,470 done is to deplete those high abundance proteins. We know for example, 38 00:02:36,470 --> 00:02:41,950 that things like albumin are actually known biomarkers. They are 39 00:02:41,950 --> 00:02:49,440 used in multiple myeloma, for instance. They are generally descriptive 40 00:02:49,440 --> 00:02:56,200 of general health and so they are valuable. Some of the questions 41 00:02:56,200 --> 00:03:00,120 though that we have are really about some of the specificities, 42 00:03:01,240 --> 00:03:06,680 even proteins like PSA which are really widely studied. We don't 43 00:03:06,680 --> 00:03:10,240 know terribly much about their post translational modifications, 44 00:03:10,240 --> 00:03:15,720 their proteoforms, albumin, same thing, its extent of modification, 45 00:03:16,590 --> 00:03:20,830 how it may be truncated and if that's informative or useful. So 46 00:03:20,830 --> 00:03:25,310 I do think that there is, there is a, there's a lot to learn 47 00:03:25,470 --> 00:03:30,270 even from variations on high abundance proteins that we, we just, 48 00:03:30,270 --> 00:03:35,390 we haven't captured at all yet. And I think the other, other 49 00:03:35,390 --> 00:03:40,990 question there is how do high abundance proteins potentially interact 50 00:03:41,070 --> 00:03:45,470 with lower abundance proteins? Albumin is a tremendous carrier. 51 00:03:45,470 --> 00:03:51,050 It is great at solubiliz. There may be signals in proteins 52 00:03:51,050 --> 00:03:54,690 that are carried along with albumin and maybe they are particularly 53 00:03:54,690 --> 00:03:57,610 carried along in some contexts or under some disease conditions 54 00:03:57,610 --> 00:04:02,450 and not in others. So there, you're absolutely right. There's 55 00:04:02,450 --> 00:04:06,530 potentially a lot of information in those top 20. I'll 56 00:04:06,530 --> 00:04:09,570 also call out that among the most abundant proteins in the blood 57 00:04:09,570 --> 00:04:14,730 are immunoglobulins. And so there is a tremendous amount of research. 58 00:04:14,730 --> 00:04:18,690 Josh Lebear's group has done a lot looking at autoantibodies and 59 00:04:18,690 --> 00:04:24,869 their variation and so those signatures are often discarded in 60 00:04:25,109 --> 00:04:30,949 common proteomics workflows. So I think there's definitely richness 61 00:04:30,949 --> 00:04:34,869 in both the top 20 and the next 10,000. 62 00:04:35,989 --> 00:04:40,949 So maybe a follow up question from my side as you talk through 63 00:04:41,909 --> 00:04:45,109 the importance of all the proteins. Do you think these next 64 00:04:45,109 --> 00:04:48,949 generation technologies which allow us now to do high throughput 65 00:04:48,949 --> 00:04:53,670 analysis of mini of these tissues of interest, that they will 66 00:04:54,150 --> 00:04:56,750 ultimately change a perspective that we only have to 67 00:04:56,750 --> 00:05:00,590 study a certain portion of it like the low abundance or because 68 00:05:00,590 --> 00:05:02,550 now we have access to all of them. 69 00:05:04,150 --> 00:05:08,590 So I, I think what we will, so I'm just, I'm going to wave my hands 70 00:05:08,590 --> 00:05:13,070 around wildly at this point. I, I, I think when, when we are given 71 00:05:13,070 --> 00:05:17,880 the option to look at everything, we know that there are 72 00:05:17,880 --> 00:05:23,040 complex interactions, quaternary interactions that occur. 73 00:05:23,600 --> 00:05:28,000 We know that there's information that occurs from not 74 00:05:28,000 --> 00:05:33,200 just protein A being up, but protein A cycling over time or the 75 00:05:33,200 --> 00:05:37,640 combination of protein A cycling over time alongside protein 76 00:05:37,640 --> 00:05:45,730 B rising or falling over time. And so those temporal trends we may 77 00:05:45,730 --> 00:05:49,450 want to look at larger numbers of proteins rather than focusing 78 00:05:49,450 --> 00:05:54,930 on just a handful so that we can really elaborate the full complexity 79 00:05:54,930 --> 00:06:02,530 of co correlations, co discordances and the temporal variation 80 00:06:02,530 --> 00:06:03,090 therein. 81 00:06:04,290 --> 00:06:08,570 Yeah. So hopefully the next time we do our annual physical checkup 82 00:06:08,570 --> 00:06:13,450 and the doctor says oh, do we want to do a full blood panel? Then 83 00:06:13,450 --> 00:06:16,630 they mean a full proteome blood panel in a addition to many 84 00:06:16,630 --> 00:06:18,110 other other panels. 85 00:06:18,350 --> 00:06:22,030 Yeah, Absolutely. You know, my lab had a paper several years ago 86 00:06:22,030 --> 00:06:26,070 where we were looking just at platelet counts, which are considered 87 00:06:26,070 --> 00:06:30,470 an incredibly vanilla measurement. It's done as part of 88 00:06:30,470 --> 00:06:37,950 every CBC test. But what we found is that there's associated 89 00:06:38,190 --> 00:06:43,200 with cancer. There's an increase in the spiking of platelet 90 00:06:43,200 --> 00:06:47,240 counts. There's not a set change. So you don't see the total 91 00:06:47,240 --> 00:06:50,200 number of platelet counts increasing, but you see an increase 92 00:06:50,280 --> 00:06:55,720 in the frequency of spikes in platelet counts. And this was data 93 00:06:56,200 --> 00:07:03,080 collected from the VA and over millions of patients. And so I think 94 00:07:03,160 --> 00:07:07,480 as we draw on richer data sets, we'll be able to figure out 95 00:07:08,160 --> 00:07:12,520 both where is the fullness of data? But we'll also be able to figure 96 00:07:12,520 --> 00:07:16,480 out for the clinical test where you actually do want the smallest, 97 00:07:16,480 --> 00:07:21,760 cheapest, most compact thing. What is that smallest, cheapest, 98 00:07:21,760 --> 00:07:22,800 most compact thing. 99 00:07:23,280 --> 00:07:27,440 So the second part of the question asks about reference intervals 100 00:07:27,440 --> 00:07:30,000 and dynamic range. Any thoughts on that? 101 00:07:30,960 --> 00:07:35,840 So I think there are. Before I dive into that, I want to just quickly 102 00:07:37,990 --> 00:07:42,270 comment on that. When we talk about the abundance of a protein 103 00:07:42,270 --> 00:07:47,110 and the difference in abundance of a protein, we often 104 00:07:47,270 --> 00:07:51,750 are asking a question about the difference between relative quantitation 105 00:07:51,750 --> 00:07:58,110 and absolute quantitation. And relative quantitation allows us to 106 00:07:58,110 --> 00:08:05,240 say, for protein A in this patient, it has changed by fourfold. 107 00:08:06,600 --> 00:08:13,560 Absolute quantitation allows us to look across proteins and say, 108 00:08:13,880 --> 00:08:19,320 all right, well, albumin was present at 4 nanograms per mil, and 109 00:08:19,480 --> 00:08:26,600 IGG was present at 3 nanograms per milliliter. And so I can establish 110 00:08:27,000 --> 00:08:33,810 relationships between proteins, not just within one particular 111 00:08:33,970 --> 00:08:40,930 protein. And that's a critical piece of information because we might, 112 00:08:40,930 --> 00:08:46,170 for instance, want to look at. I'll come back to what we were talking 113 00:08:46,170 --> 00:08:50,450 about before in terms of autoantibodies. If we look at cases, 114 00:08:50,690 --> 00:08:54,890 particularly in autoimmunity, things like multiple sclerosis, we 115 00:08:54,890 --> 00:09:01,890 may want to be able to say not only, oh, this viral mimic of myelin 116 00:09:01,890 --> 00:09:08,170 basic protein is up, we may actually want to look at the relationship 117 00:09:08,650 --> 00:09:14,650 between the viral protein going from 3 units to 10 units alongside 118 00:09:14,810 --> 00:09:20,210 the auto antibody going from 10 units to 100 units, and it being 119 00:09:20,210 --> 00:09:24,930 the ratio of that 100 units of autoantibody to 10 units of viral 120 00:09:24,930 --> 00:09:30,030 protein, that is the ultimate predictor. So that ability to look 121 00:09:30,030 --> 00:09:36,390 across proteins is really what is enabled by having absolute quantitation. 122 00:09:37,270 --> 00:09:43,670 Also buried in that question is this question is trends and what 123 00:09:43,670 --> 00:09:49,510 does normal look like right now? For some proteins, we have very 124 00:09:49,510 --> 00:09:54,590 good understanding of how they vary over time and how they vary 125 00:09:54,590 --> 00:09:58,590 in different populations and subpopulations. But that's not true 126 00:09:58,590 --> 00:10:01,670 for most proteins and that's particularly not true for the very 127 00:10:01,670 --> 00:10:05,950 low abundance proteins where we really just don't know what normal 128 00:10:05,950 --> 00:10:09,990 is. And so it's very hard for us to say what disease is. 129 00:10:11,350 --> 00:10:15,750 Excellent insight, an excellent question. So maybe we can 130 00:10:16,230 --> 00:10:20,390 go and look at the second question here. Paragraph. We have 131 00:10:20,390 --> 00:10:24,990 a question here from Pratt K. Who asks, can you share examples 132 00:10:24,990 --> 00:10:28,590 where pharmaceutical companies have used protein detection platforms 133 00:10:28,590 --> 00:10:33,030 to assay samples, particular cases that led to the key scientific 134 00:10:33,030 --> 00:10:37,430 or clinical insights or supported the development of a therapeutic 135 00:10:37,430 --> 00:10:42,790 or diagnostic product? Wide ranging question. So can you take 136 00:10:42,790 --> 00:10:43,630 a stab at that? 137 00:10:46,200 --> 00:10:52,520 Well, that's a deep question you hear all the time about the potential 138 00:10:52,520 --> 00:10:56,200 for proteomics to revolutionize drug and diagnostic 139 00:10:56,200 --> 00:11:01,600 development. And what are the real world examples? I think the 140 00:11:01,600 --> 00:11:06,280 best way for us to answer this question is really I'd like to phone 141 00:11:06,280 --> 00:11:11,080 a friend who is actively using proteomics for therapeutic development. 142 00:11:12,130 --> 00:11:15,970 His name's Don Kirkpatrick. For many years he was a director 143 00:11:16,130 --> 00:11:20,090 at Genentech and then most recently a senior vice president 144 00:11:20,090 --> 00:11:24,570 at Zyra Therapeutics where they, according to their LinkedIn 145 00:11:24,570 --> 00:11:28,210 profile, seek to rethink the drug discovery and development process 146 00:11:28,210 --> 00:11:34,330 from end to end. Don is the, is really the perfect person to talk 147 00:11:34,330 --> 00:11:39,430 to about this. So if you don't mind, I'd really love to to phone 148 00:11:39,430 --> 00:11:41,310 a friend to answer this. 149 00:11:42,190 --> 00:11:43,310 So let's do that then. 150 00:11:44,590 --> 00:11:48,790 So I'm very delighted to welcome to my phone a friend, Don 151 00:11:48,790 --> 00:11:55,990 Kirkpatrick, who has a rich history of first being a leader in 152 00:11:55,990 --> 00:12:00,630 proteomics methods and then applying those methods first at Genentech 153 00:12:00,630 --> 00:12:07,220 and then at Zyra to really diving deep into developing new drug 154 00:12:07,220 --> 00:12:10,380 targets, understanding drug mechanisms. And so for this question 155 00:12:10,460 --> 00:12:14,540 I thought Don would be the absolute perfect person to talk to. 156 00:12:14,700 --> 00:12:18,220 So Don, thank you so much for being here with us today. 157 00:12:18,700 --> 00:12:21,460 Yeah, it's a pleasure to be with you Parag, and fun to continue 158 00:12:21,460 --> 00:12:23,620 the conversation that we've been running in the background for 159 00:12:23,620 --> 00:12:24,220 a long time. 160 00:12:24,540 --> 00:12:28,620 Absolutely. Well, so I'm going to turn it over to you and we hear 161 00:12:28,620 --> 00:12:32,470 about proteomics being important in pharmaceutical companies 162 00:12:32,470 --> 00:12:37,110 and in drug development. Can you give us a couple concrete examples 163 00:12:37,110 --> 00:12:40,310 that share with our listeners? Viewers? 164 00:12:41,110 --> 00:12:44,710 Yeah, for sure. So I think, you know, proteomics has sort of 165 00:12:44,710 --> 00:12:48,630 grown over these, these recent years into having a more and more 166 00:12:48,790 --> 00:12:53,910 influential role in drug day to day drug discovery across, across 167 00:12:53,910 --> 00:12:57,670 the field and that involves large molecule and small molecule 168 00:12:57,670 --> 00:13:00,990 therapeutics. You know, the ones that I think most actively about 169 00:13:00,990 --> 00:13:04,590 are in the small molecule domain really because proteomics 170 00:13:04,590 --> 00:13:08,070 has the ability to understand targets in a rich and sophisticated 171 00:13:08,070 --> 00:13:10,990 way. So I did some, some thinking about ways and places that 172 00:13:11,070 --> 00:13:13,310 it's had a big impact. And there's a couple of them that are, 173 00:13:13,470 --> 00:13:17,310 I think are really like front and center and growing in their, 174 00:13:17,310 --> 00:13:20,870 in their influence. One of the ones that really struck me was a 175 00:13:20,870 --> 00:13:25,110 paper that came from Steve Carr's group and the group at the 176 00:13:25,110 --> 00:13:28,700 Broad many years ago that really was sort of the gateway into, 177 00:13:28,930 --> 00:13:33,930 into Cereblon based targeted protein degradation. And it was the 178 00:13:33,930 --> 00:13:38,970 discovery that lenolinamide led to the degradation of the Icarus 179 00:13:38,970 --> 00:13:42,930 transcription factor through an E3 ubiquitin ligase in the Cul4 180 00:13:43,010 --> 00:13:46,410 family with a substrate adapter known as Cereblon. And that 181 00:13:46,410 --> 00:13:49,170 was a discovery that was made in a couple of different dimensions. 182 00:13:49,170 --> 00:13:53,810 But one of those was mass spec proteomics. And from there then that 183 00:13:53,810 --> 00:13:57,290 ubiquitin ligase and a number of others in that family really have 184 00:13:57,290 --> 00:14:01,750 grown in their impact and influence. And you know, the, the 185 00:14:01,750 --> 00:14:04,350 different ways that that groups have gone after trying to 186 00:14:04,350 --> 00:14:09,310 utilize them to specifically target certain substrates for degradation. 187 00:14:09,470 --> 00:14:13,910 And what was the proteomics component? Was it discovering the 188 00:14:13,910 --> 00:14:18,710 particular ubiquitin ligase? Was it seeing that it was upregulated 189 00:14:18,710 --> 00:14:22,510 in a particular system? How did proteomics play a role in that 190 00:14:22,670 --> 00:14:24,030 mechanistic discovery? 191 00:14:24,270 --> 00:14:27,780 And of course I will say, you know, in, in papers, as we all know, 192 00:14:28,020 --> 00:14:32,380 the story gets told in a way that helps to make sure that the 193 00:14:32,380 --> 00:14:35,660 reader can get it. So if you take it at face value in terms of 194 00:14:35,660 --> 00:14:40,300 the order of events, the first event, the first discovery that was 195 00:14:40,300 --> 00:14:45,500 described in that paper was what we call digly proteomics or 196 00:14:45,500 --> 00:14:50,420 KGG profiling of ubiquitinated substrates. And they identified specific 197 00:14:50,420 --> 00:14:54,720 ubiquitination events marked by this diglycine remnant of ubiquitin 198 00:14:55,110 --> 00:15:01,270 on the Ikaros transcription factor that were induced by linolenomide 199 00:15:01,270 --> 00:15:06,630 in cells. And from that then came the sort of follow on discoveries 200 00:15:06,630 --> 00:15:10,749 around the full mechanism of how that was playing out. But the 201 00:15:10,749 --> 00:15:14,550 seminal discovery in that paper was the actual mark of the 202 00:15:14,550 --> 00:15:19,070 ubiquitination and then the field as a whole. And it's hard to 203 00:15:19,070 --> 00:15:24,150 tell how much and who's doing what. But it's clear that across 204 00:15:24,230 --> 00:15:27,810 the field of targeted protein degrad that there are a multitude 205 00:15:27,810 --> 00:15:30,610 of groups that are using mass spec in a variety of different ways 206 00:15:30,610 --> 00:15:34,170 to try to understand the mechanisms, the targets and the enzyme 207 00:15:34,170 --> 00:15:35,890 enzymatic machinery that are Involved. 208 00:15:36,450 --> 00:15:39,970 That's interesting because you could imagine that proteomics in 209 00:15:39,970 --> 00:15:44,050 that context would dominantly be used to say, is the protein here 210 00:15:44,050 --> 00:15:49,370 or not? Just as sort of a fancy Western really. But what you're 211 00:15:49,370 --> 00:15:52,090 describing is actually much, much more sophisticated than that. 212 00:15:52,090 --> 00:15:55,890 It's finding what are the targets, what are the off targets 213 00:15:56,520 --> 00:16:01,400 and what are the compensating pathways that are impacted as well. 214 00:16:02,120 --> 00:16:05,800 So those two play nicely together. The idea that a protein 215 00:16:05,800 --> 00:16:09,880 goes away completely is often seen, but because it's series of 216 00:16:09,880 --> 00:16:12,920 steps downstream, mechanistically you have to then 217 00:16:12,920 --> 00:16:17,560 sort of move in proximal in the time dimension to really understand 218 00:16:17,560 --> 00:16:20,120 what the drug is doing. And I think that's why this particular 219 00:16:20,360 --> 00:16:24,200 example and this particular piece of data that started that was 220 00:16:24,200 --> 00:16:27,200 so compelling. But yes, I think global proteome profiling as 221 00:16:27,200 --> 00:16:31,540 a way to understand how a drug remodels the proteome has been effective. 222 00:16:31,540 --> 00:16:34,860 In fact, there's some really new and interesting work that came 223 00:16:34,860 --> 00:16:39,100 out of Vishwadiksik's group at Genentech led by Ada Nadoja that 224 00:16:39,100 --> 00:16:43,380 showed that an ERK inhibitor specifically triggers a degradation 225 00:16:43,460 --> 00:16:49,060 of an ETV family transcription factor as effectively the one and 226 00:16:49,060 --> 00:16:52,260 only protein that's degraded in the first 30 minutes after drug 227 00:16:52,260 --> 00:16:53,300 treatment in. 228 00:16:53,460 --> 00:16:58,180 And this is not a targeted degrader, this is an ERK targeting 229 00:16:59,120 --> 00:17:02,480 kinase inhibitor leading to a protein degradation. 230 00:17:02,800 --> 00:17:08,120 Exactly. So it is an ERK kinase activity dependent degradation 231 00:17:08,120 --> 00:17:12,760 event that when you inhibit the kinase, you trigger the inducible 232 00:17:12,760 --> 00:17:15,800 degradation of this particular transcription factor. And that's 233 00:17:15,800 --> 00:17:17,960 a paper that was just published even in the last couple 234 00:17:17,960 --> 00:17:22,560 of weeks. So to say there are these types of activities underlying 235 00:17:22,640 --> 00:17:25,720 many of the molecules that have been used effectively in the 236 00:17:25,720 --> 00:17:29,970 clinic for a long time. And as proteomics really sort of positions 237 00:17:29,970 --> 00:17:34,530 itself alongside other technologies, we are starting to 238 00:17:34,530 --> 00:17:38,450 see the full multitude of mechanisms that are in play when 239 00:17:38,450 --> 00:17:42,770 drugs come into contact with the target cells, but potentially 240 00:17:42,770 --> 00:17:47,010 also with off target cells and you know, manifesting as off target 241 00:17:47,010 --> 00:17:48,330 activities in some of those. 242 00:17:49,290 --> 00:17:52,650 So when we, when we hear people chat in this space, and I'd 243 00:17:52,650 --> 00:17:57,210 just like to get your perspectives on this, we hear, oh, 244 00:17:57,210 --> 00:18:00,850 hey, proteomics is just used at the front end to see what's different 245 00:18:01,410 --> 00:18:06,250 between healthy and disease. And so it's your sort of initial 246 00:18:06,250 --> 00:18:12,450 target finding. But what you're describing is not just that 247 00:18:12,610 --> 00:18:15,930 you're describing all throughout the drug development journey 248 00:18:15,930 --> 00:18:19,330 that proteomics is playing a role. Absolutely. 249 00:18:19,330 --> 00:18:23,010 And in fact it certainly has a strong role. In the beginning, I 250 00:18:23,010 --> 00:18:26,330 think some of the work that we had Done even in the early days of 251 00:18:26,330 --> 00:18:30,950 my drug discovery career was in identifying those markers that 252 00:18:30,950 --> 00:18:34,790 could then be used to screen for and ultimately identify those 253 00:18:34,790 --> 00:18:38,950 early lead molecules for targets such as the LRRK2 kinase 254 00:18:38,950 --> 00:18:42,390 in Parkinson's disease. But as you start thinking about, you know, 255 00:18:42,390 --> 00:18:45,670 programs and the multitude of effects that they have in living 256 00:18:45,670 --> 00:18:49,470 organisms, understanding the diversity of effects that that small 257 00:18:49,470 --> 00:18:54,790 or even large, large molecule therapeutic have on cells and tissues 258 00:18:55,030 --> 00:18:58,430 is perfectly positioned for proteomics to have that impact. And 259 00:18:58,430 --> 00:19:02,910 it's done so repeatedly now in places like Genentech and Zahra and 260 00:19:02,910 --> 00:19:07,470 a number of other companies that, that are, you know, investing 261 00:19:07,470 --> 00:19:07,990 in the technology. 262 00:19:09,430 --> 00:19:15,110 And so what. So you shared one really beautiful example from your 263 00:19:15,110 --> 00:19:20,270 own career. Can. What is your favorite example of where you used 264 00:19:20,270 --> 00:19:23,130 proteomics to inform therapeutic development? 265 00:19:24,410 --> 00:19:26,810 That's a fun question because I spent some time thinking about 266 00:19:26,810 --> 00:19:32,570 this recently and there's a molecule that recently went through 267 00:19:32,570 --> 00:19:36,290 and received approval and it really was based on an understanding 268 00:19:36,290 --> 00:19:41,850 that came from mass spec proteomic results. So there was an 269 00:19:42,010 --> 00:19:47,050 idea that one could selectively inhibit mutant PI3 kinase 270 00:19:47,450 --> 00:19:50,200 over the wild type protein. And if you could do that, then you 271 00:19:50,200 --> 00:19:52,680 could get around some of the side effects that come from broadly 272 00:19:52,680 --> 00:19:57,880 inhibiting PI3 kinase in normal cells and tissues. And an 273 00:19:57,880 --> 00:20:00,360 investigator, Lori Friedman at Genentech, came one day and said, 274 00:20:00,360 --> 00:20:03,320 hey, I have a molecule and has some interesting effects and it's 275 00:20:03,320 --> 00:20:06,360 only working in mutant cells. You know, is there a way to show 276 00:20:06,360 --> 00:20:09,920 that in fact it is having an effect on the mutant protein selectively? 277 00:20:09,920 --> 00:20:13,840 And so we did that because several of the different pi3 kinase 278 00:20:13,840 --> 00:20:17,780 mutants have proteotypic peptides, a peptide that will tell 279 00:20:17,780 --> 00:20:21,900 you that the mutant that will tell the difference between the mutant 280 00:20:21,900 --> 00:20:25,220 protein and the wild type protein. And indeed you could show 281 00:20:25,220 --> 00:20:29,980 that in cells that expressed one or another form of mutant pi3 282 00:20:29,980 --> 00:20:35,100 kinase, that only the mutant protein as read out by that one mutant 283 00:20:35,100 --> 00:20:39,340 selective peptide was being degraded where the wild type protein 284 00:20:39,340 --> 00:20:42,550 was being spared when the cells were treated with this particular 285 00:20:42,550 --> 00:20:45,870 molecule that's now known as Involisib. 286 00:20:46,670 --> 00:20:51,470 Wow, that's, that's really a beautiful story of how the specificity 287 00:20:52,990 --> 00:20:55,990 is, is critical in understanding and how the proteomics 288 00:20:55,990 --> 00:21:01,110 played a key role. Because if you, if you, again, if you not to 289 00:21:01,110 --> 00:21:04,510 pick on westerns, but if you just had a western against the total 290 00:21:04,510 --> 00:21:08,030 protein, you wouldn't be able to see that mechanism at all. 291 00:21:08,830 --> 00:21:12,190 Yeah, in that case there's one specific residue that differs between 292 00:21:12,190 --> 00:21:15,710 the wild type and the mutant and it confers a multitude of different 293 00:21:16,030 --> 00:21:19,310 effects downstream. But as a readout, that's the one and only 294 00:21:20,270 --> 00:21:23,550 readout that you would have. And you'd need to have a detection 295 00:21:23,550 --> 00:21:26,590 reagent, an antibody, or some other probe that specifically allowed 296 00:21:26,590 --> 00:21:29,710 you to do that. But how does that work? If you have a mutant, 297 00:21:30,270 --> 00:21:34,430 a kinase like pi3kinase, that has different mutations across its 298 00:21:34,590 --> 00:21:38,990 spectrum, you'd need a mutant assay for each. But it's interesting 299 00:21:38,990 --> 00:21:41,630 to think a little bit about because, you know, in the context 300 00:21:41,630 --> 00:21:44,790 of mutant specific degradation, this same sort of process 301 00:21:44,790 --> 00:21:48,390 has played out with KRAS, particularly starting with the KRAS 302 00:21:48,390 --> 00:21:53,550 G12C where Amgen has the G12C specific KRAS inhibitor. And that 303 00:21:53,550 --> 00:21:56,670 again started with an assay that allowed them to show that that 304 00:21:56,670 --> 00:22:01,270 molecule specifically engaged cysteine 12, which is the mutation 305 00:22:01,990 --> 00:22:07,590 in the KRAS molecule, and, you know, led to the cellular effects 306 00:22:07,590 --> 00:22:10,910 that they ultimately were able to demonstrate. So that one proteotypic 307 00:22:10,910 --> 00:22:14,470 readout became the foundational piece of the entire 308 00:22:14,470 --> 00:22:16,550 KRASG12C inhibition story. 309 00:22:17,510 --> 00:22:21,870 Don, we've talked a lot about how proteomics has helped you so 310 00:22:21,870 --> 00:22:26,870 far, but there are probably areas where you wish you could further 311 00:22:26,870 --> 00:22:30,870 apply proteomics or where you wish technologies were more advanced 312 00:22:30,870 --> 00:22:34,610 to be able to ask different questions. Tell me a little bit about 313 00:22:35,090 --> 00:22:38,370 how you view the future and the unexplored. 314 00:22:38,930 --> 00:22:42,170 Yeah, there's a few dimensions that I'd love to be able to dive 315 00:22:42,170 --> 00:22:45,730 into and that that are starting to emerge from technologies 316 00:22:45,730 --> 00:22:48,450 like the ones being developed at Nautilus. And I think the one 317 00:22:48,450 --> 00:22:51,010 that I've thought about a lot, and certainly you and I have talked 318 00:22:51,010 --> 00:22:54,490 a lot about, is around proteoforms, because while we think 319 00:22:54,490 --> 00:22:58,170 of an MRNA and we think of a protein and maybe a post translational 320 00:22:58,170 --> 00:23:02,610 modification or two on a protein, in fact, any given protein 321 00:23:02,610 --> 00:23:05,570 molecule can exist in a multitude of different states, what 322 00:23:05,570 --> 00:23:09,850 we refer to as proteoforms. And to date it has been nearly impossible 323 00:23:09,850 --> 00:23:14,090 to characterize the proteoform repertoire of any protein, let alone 324 00:23:14,090 --> 00:23:18,970 the proteoform repertoire of a given cell or cell type. And I think 325 00:23:18,970 --> 00:23:23,010 those are the kinds of approaches that are coming to bear 326 00:23:23,010 --> 00:23:26,330 from groups like Nautilus. And so I'm quite excited to think about 327 00:23:26,410 --> 00:23:30,310 how would we, how would we use the information about proteoforms 328 00:23:30,310 --> 00:23:33,830 if we had access to it and if we could do those types of analyses 329 00:23:33,830 --> 00:23:37,030 systematically, whether it be for the drug targets that we care 330 00:23:37,030 --> 00:23:41,030 about specifically, or in a grand sense for the entirety of the 331 00:23:41,030 --> 00:23:43,390 proteome of a cell tissue or organism. 332 00:23:43,950 --> 00:23:46,910 Yeah, Mel, that's a, that's a really beautiful future and definitely 333 00:23:46,910 --> 00:23:51,190 one that, that we've been working on. And I'm, I'm excited 334 00:23:51,190 --> 00:23:55,150 about having folks like you take advantage of that knowledge 335 00:23:55,150 --> 00:23:59,430 to push the boundaries on our next generation of therapeutics. 336 00:24:00,150 --> 00:24:01,030 The day is here. 337 00:24:02,150 --> 00:24:05,950 So Don, one last maybe contentious question to just put 338 00:24:05,950 --> 00:24:10,030 you on the spot. We often hear people saying, oh well, I don't really 339 00:24:10,030 --> 00:24:13,510 need proteomics, I can just RNA seq everything and that's good 340 00:24:13,510 --> 00:24:17,630 enough for my therapeutic development. I'd love to hear your 341 00:24:17,630 --> 00:24:17,990 thoughts. 342 00:24:18,710 --> 00:24:22,850 Yeah, no, RNA seq has a clear, a clear place in understanding the 343 00:24:22,850 --> 00:24:26,010 cellular phenotypes that we are monitoring in the context of 344 00:24:26,010 --> 00:24:29,130 drug discovery. But you can't get away from actually measuring 345 00:24:29,130 --> 00:24:34,290 the protein itself. All kinds of post translational controls that 346 00:24:34,290 --> 00:24:38,570 are occurring on cells and on the proteins within cells are those 347 00:24:38,650 --> 00:24:41,650 that are directly being impacted by our drugs when they go 348 00:24:41,650 --> 00:24:44,330 in and hit their target and ultimately manifest this downstream 349 00:24:44,330 --> 00:24:47,970 activities. And you can see that with both intracellular targets, 350 00:24:47,970 --> 00:24:53,040 but also with the targets of, of biotherapeutics where you're engaging 351 00:24:53,040 --> 00:24:57,960 a specific protea form, maybe a modified form or a proteoform that's 352 00:24:57,960 --> 00:25:01,400 in a specific three dimensional confirmation. The kinds 353 00:25:01,400 --> 00:25:05,480 of readouts that you can get from proteomics that are encoded, 354 00:25:05,720 --> 00:25:08,880 but they're encoded not just in the transcript level of the target 355 00:25:08,880 --> 00:25:11,960 itself, but really in the full understanding of what's happening 356 00:25:11,960 --> 00:25:13,320 functionally within a cell. 357 00:25:13,720 --> 00:25:17,000 Yeah, that makes great sense. Some of the examples you've talked 358 00:25:17,000 --> 00:25:22,410 about about changes in protein degradation rate, those are not going 359 00:25:22,410 --> 00:25:26,930 to be well captured by the transcript changes in its extent 360 00:25:26,930 --> 00:25:30,050 of phosphorylation or modification with ubiquitin. 361 00:25:30,210 --> 00:25:33,370 Well, so many of these are interplaying with one another that 362 00:25:33,370 --> 00:25:37,330 phosphorylation is often controlling the engagement of enzymes 363 00:25:37,330 --> 00:25:40,450 like ubiquitin ligases that ultimately control downstream effects 364 00:25:40,450 --> 00:25:44,810 such as ubiquitination and the turnover of the protein. None of 365 00:25:44,810 --> 00:25:48,330 which would be directly measurable at the level of the mRNA, 366 00:25:48,330 --> 00:25:52,170 since all of that is happening downstream at the protein level. 367 00:25:52,730 --> 00:25:55,610 Awesome. Well, I think we've answered our question, but I think 368 00:25:55,610 --> 00:26:00,570 we could probably chat about this topic for hours and probably 369 00:26:00,570 --> 00:26:04,850 have four hours and so I reserve the right to invite you back 370 00:26:04,850 --> 00:26:06,730 on at another time. 371 00:26:07,610 --> 00:26:10,050 Yeah, it was great to see you today, Barag, and thanks for, thanks 372 00:26:10,050 --> 00:26:10,730 for checking in. 373 00:26:10,810 --> 00:26:15,290 Yeah, thank you so much for joining us today, Don. Huge thanks 374 00:26:15,290 --> 00:26:18,620 for such an insightful answer to this very important question. 375 00:26:20,060 --> 00:26:24,540 Yeah, this was really great and I can't wait until the Nautilus 376 00:26:24,540 --> 00:26:26,540 platform is used in a similar effort. 377 00:26:27,660 --> 00:26:31,180 Yes, definitely. But in the meantime, let's get to our next question. 378 00:26:32,220 --> 00:26:35,620 All right. The next question focuses on lifestyle and how it impacts 379 00:26:35,620 --> 00:26:39,900 the proteome. So our third question came from Alberto Achina, 380 00:26:40,380 --> 00:26:45,870 1115 who says it would be interesting to know how food, physical 381 00:26:45,870 --> 00:26:50,470 exercise, thoughts or feelings affect the proteome. I'd love to 382 00:26:50,470 --> 00:26:57,950 take this one and then maybe you can add what you know about this 383 00:26:58,350 --> 00:26:59,310 particular area. 384 00:27:00,030 --> 00:27:03,870 Go for it. And if I have anything to add, I'll jump in later. 385 00:27:04,430 --> 00:27:09,910 So the proteome was a focus of in food was a focus of the episode 386 00:27:09,910 --> 00:27:13,710 17 where we talked about how proteomics can contribute to food 387 00:27:13,710 --> 00:27:17,210 security, security, food safety, but also in authenticity 388 00:27:17,210 --> 00:27:21,050 testing. So I encourage you to listen to that particular episode. 389 00:27:22,090 --> 00:27:26,650 What I would also do or like to do is connect that food aspect 390 00:27:27,210 --> 00:27:31,650 to the last part of your question, which is knowledge, sorry, 391 00:27:31,650 --> 00:27:37,610 feelings. And there is actually a very well established 392 00:27:37,610 --> 00:27:42,580 connection between food intake and what's called the gut brain axis. 393 00:27:44,260 --> 00:27:48,340 It turns out the food you intake is tightly linked to emotions 394 00:27:49,700 --> 00:27:53,780 because the food is digested in your gut by trillions of bacteria, 395 00:27:54,100 --> 00:27:59,420 about 3,000 species, 3,000 different species in your gut and 396 00:27:59,420 --> 00:28:04,020 they produce small neurotransmitters that ultimately 397 00:28:04,020 --> 00:28:08,960 communicate with the brain and the immune system. So you definitely 398 00:28:09,360 --> 00:28:14,280 affecting or the proteome that you take in as food is definitely 399 00:28:14,280 --> 00:28:21,840 affecting your feelings and your thoughts. So as people often 400 00:28:22,000 --> 00:28:26,400 say, what you are, what you eat is holding true in this particular 401 00:28:26,480 --> 00:28:31,040 case. And then there's the strong connection how the connection 402 00:28:31,040 --> 00:28:35,240 between brain and immune system essentially affect the rest 403 00:28:35,240 --> 00:28:40,800 of the body. And so in this case I strongly encourage you to 404 00:28:40,960 --> 00:28:47,200 again listen to episode 17 to learn more about how proteomics and 405 00:28:47,200 --> 00:28:50,160 food is connected. Any other thoughts on that? 406 00:28:51,600 --> 00:28:55,760 Just that I think our physiology is such a complex adaptive 407 00:28:55,760 --> 00:29:01,910 system and so the arpidium, we just talked about this, the serum 408 00:29:01,910 --> 00:29:07,710 and circulating proteome and I am 100% certain that my circulating 409 00:29:07,710 --> 00:29:11,390 proteome is going to be impacted whether I have pizza versus 410 00:29:11,390 --> 00:29:17,350 quinoa and so how it's impacted. There's some really great 411 00:29:17,350 --> 00:29:21,710 researchers. The Lampe group at the Fred Hutchinson Cancer center 412 00:29:21,870 --> 00:29:25,390 has done a number of studies putting people on controlled diets 413 00:29:25,790 --> 00:29:31,880 and observing how that impacts their, their cancer progression. 414 00:29:32,520 --> 00:29:38,680 As well as we've seen a lot of work looking at anti inflammatory 415 00:29:39,240 --> 00:29:43,720 factors and it would be really interesting to see can we observe 416 00:29:43,720 --> 00:29:48,440 a clear proteomic indication from the anti inflammatory diet versus 417 00:29:48,440 --> 00:29:53,080 not. I think there's a lot of very fun science to be done there. 418 00:29:54,770 --> 00:30:00,170 Yes, I agree. The second part of the question here is around the 419 00:30:00,170 --> 00:30:05,410 proteome and physical exercise. Now this could be its own 420 00:30:06,050 --> 00:30:11,810 podcast series essentially, but I think from a very large perspective 421 00:30:12,290 --> 00:30:16,130 what you can see is that obviously the proteome is affected 422 00:30:16,130 --> 00:30:19,970 through physical exercise. And there's plenty of research that shows 423 00:30:19,970 --> 00:30:24,680 that essentially exercise affects your TCA cycle, the mitral 424 00:30:25,000 --> 00:30:30,560 functions, obviously all the muscle related functions. And people 425 00:30:30,560 --> 00:30:34,600 have shown over and over again in many, many different studies that 426 00:30:37,080 --> 00:30:41,640 the benefits of physical exercise clearly manifest itself 427 00:30:41,640 --> 00:30:46,360 in the changes in the proteome. In fact, it's now being 428 00:30:46,760 --> 00:30:50,920 used as markers in some of the plasma proteomics studies that are 429 00:30:50,920 --> 00:30:56,820 merging now, where there's a lot of indication that a plasma proteome 430 00:30:57,780 --> 00:31:02,100 from a person that's healthy and exercising looks very different 431 00:31:02,100 --> 00:31:09,220 from a person that is not exercising and might actually have 432 00:31:09,220 --> 00:31:14,220 the potential for disease. Clearly, physical exercise changes 433 00:31:14,220 --> 00:31:18,340 you, changes the proteome and in many cases all the indications 434 00:31:18,420 --> 00:31:25,620 are that it actually affects you positively. Is there a control 435 00:31:25,700 --> 00:31:29,700 group? And I think Parag, I think you're familiar with that. 436 00:31:29,780 --> 00:31:33,180 But we have sent people to space where there's no gravity and 437 00:31:33,180 --> 00:31:37,779 so it's very difficult to have physical exercise. And again, research 438 00:31:37,860 --> 00:31:42,660 shows that when you look at these astronauts that come back after 439 00:31:42,980 --> 00:31:48,620 days, weeks and often months being in space, they show distinct 440 00:31:48,780 --> 00:31:55,380 changes to their proteome, particularly the proteome associated 441 00:31:55,380 --> 00:31:59,700 with muscle, muscle activity. But then they also show some changes 442 00:31:59,700 --> 00:32:07,900 in their defensive functions like in oxidative stress. Again, 443 00:32:07,900 --> 00:32:11,660 the mitochondria very much affected how they're being remodeled 444 00:32:11,740 --> 00:32:15,220 from a lipid, but also from a proteome perspective. And there in 445 00:32:15,220 --> 00:32:20,420 fact is a very, very good resource on the hupo.org G web page 446 00:32:20,420 --> 00:32:23,980 that you can go to and read a lot of interesting articles about 447 00:32:23,980 --> 00:32:27,700 it. But I think Bharag, you have done some work in that area. 448 00:32:27,860 --> 00:32:30,180 So any thoughts? 449 00:32:30,740 --> 00:32:34,660 Well, so I, first off, we'll definitely link all of these resources 450 00:32:34,660 --> 00:32:38,540 that Andreas mentioned down below in the description and the 451 00:32:38,540 --> 00:32:44,630 papers of that primary data. I think the, the research that we've 452 00:32:44,630 --> 00:32:53,870 done in our lab has, we've been asking questions initially about 453 00:32:53,870 --> 00:33:00,350 diagnostics and how exercise affected the proteome in ways that 454 00:33:00,350 --> 00:33:06,110 might confound diagnostics. And one of the things that motivated 455 00:33:06,110 --> 00:33:10,480 this was actually work that was done in, in circulating tumor 456 00:33:10,480 --> 00:33:14,280 DNA where they found that there's a tremendous amount of cell 457 00:33:14,280 --> 00:33:19,480 death that occurs with, with, you know, aerobic exercise that led 458 00:33:19,480 --> 00:33:25,240 to spikes in circulating tumor DNA. Well, circulating general DNA 459 00:33:25,320 --> 00:33:28,440 showing up in the blood at higher levels and that that could 460 00:33:28,440 --> 00:33:31,880 then be confounded for circulating tumor DNA when it's really 461 00:33:31,880 --> 00:33:38,530 just from. From cell damage. The what Our early studies seem to 462 00:33:38,530 --> 00:33:44,130 suggest that the levels of protein shed by exercise, particularly 463 00:33:44,130 --> 00:33:48,530 ones that looked like epithelial cell overall, seemed much 464 00:33:48,530 --> 00:33:55,210 more modest relative to what you were seeing from the CTDNA confounder. 465 00:33:55,210 --> 00:33:59,170 And so that was already sort of an interesting early finding. 466 00:33:59,170 --> 00:34:00,730 We haven't published that data yet, though. 467 00:34:02,580 --> 00:34:06,700 Yeah, I think the other aspect that is often mentioned in the literature 468 00:34:06,700 --> 00:34:13,180 is that if you do exercise, it actually activates the mechanisms 469 00:34:13,180 --> 00:34:17,460 that actually contribute to the regeneration of the proteome. 470 00:34:17,460 --> 00:34:22,660 So damaged proteins, proteins that are no longer needed or required, 471 00:34:22,980 --> 00:34:26,660 are then being efficiently degraded. And I think that's really. 472 00:34:28,100 --> 00:34:32,100 Exercise is really an effort to take the trash out of your cells 473 00:34:32,960 --> 00:34:36,080 and rejuvenate your proteome. And so there's lots of interesting 474 00:34:36,560 --> 00:34:40,440 articles on that. And so I encourage people to read up more 475 00:34:40,440 --> 00:34:43,680 about this particular benefit of physical exercise. 476 00:34:44,400 --> 00:34:48,400 All right, our final question for the day comes from George Blumenthal, 477 00:34:48,400 --> 00:34:51,600 who I believe both of us have met at various conferences. Hey, 478 00:34:51,600 --> 00:34:56,480 George, thanks so much for your question. George asks, you've 479 00:34:56,720 --> 00:35:01,490 announced that Nautilus's targeted approach can quantify over 480 00:35:01,490 --> 00:35:06,970 2000 protea forms of tau. How does Nautilus's technology create 481 00:35:06,970 --> 00:35:14,050 a unique breakthrough in terms of tau and Alzheimer's disease? I 482 00:35:14,050 --> 00:35:16,889 think we can each take different aspects of this question. 483 00:35:18,090 --> 00:35:19,290 Yeah, absolutely. 484 00:35:21,130 --> 00:35:26,010 So maybe I'll just start by talking a little bit about proteoforms 485 00:35:26,010 --> 00:35:31,640 in general and why we feel that they are potentially really 486 00:35:33,640 --> 00:35:37,880 have an important role in Alzheimer's disease. First off, as 487 00:35:37,880 --> 00:35:42,200 just a reminder for our listeners that proteoforms are those 488 00:35:44,040 --> 00:35:49,920 the variants of proteins that arise through a combination of alternative 489 00:35:49,920 --> 00:35:54,840 splicing and potentially multiple post translational modifications. 490 00:35:55,480 --> 00:36:00,800 So for instance, in tau, in Alzheimer's disease, the protein 491 00:36:00,800 --> 00:36:04,880 tau, which is very influential, has six different alternative 492 00:36:04,880 --> 00:36:08,880 splicing forms and has been shown to have potentially dozens 493 00:36:08,880 --> 00:36:13,320 of different phosphorylations and methylations, et cetera, and 494 00:36:13,320 --> 00:36:17,080 you might see combinations of those present on the same molecule, 495 00:36:17,080 --> 00:36:21,000 you know, two, three, four or more different phosphorylations. 496 00:36:22,330 --> 00:36:28,650 Now, the challenges that we often face in studying neurodegenerative 497 00:36:28,650 --> 00:36:35,210 diseases and even studying tau, we have very clear endpoints. 498 00:36:35,530 --> 00:36:41,930 We can tell when cells have tau tangles, when extracellular regions 499 00:36:41,930 --> 00:36:48,980 have a beta plaques, where we have cell death, but those are extremely 500 00:36:49,060 --> 00:36:57,020 late measures of the process of Alzheimer's disease. One, there 501 00:36:57,020 --> 00:37:00,900 are really two places where I'm very Excited about our platform 502 00:37:02,660 --> 00:37:08,580 helping get to a new stage in Alzheimer's disease. The first is 503 00:37:08,580 --> 00:37:13,710 just being able to maybe look at the process as early as possible 504 00:37:14,190 --> 00:37:21,470 that led to disease. Where did those early polymers come from before 505 00:37:21,470 --> 00:37:26,550 they became tangles? What happened in cellular physiology? 506 00:37:26,550 --> 00:37:32,590 Did we see changes that were associated with oxidative stress 507 00:37:32,590 --> 00:37:36,630 or damage control that are associated with particular forms 508 00:37:36,630 --> 00:37:42,910 or sets of proteforms? And to date that's been very hard to measure. 509 00:37:43,150 --> 00:37:46,670 It's been hard to say, oh, there's this triple phosphorylation, 510 00:37:47,070 --> 00:37:50,750 that's a higher abundance alongside this quadruple phosphorylation, 511 00:37:51,150 --> 00:37:56,350 and that is associated with middle stage Alzheimer's disease 512 00:37:56,670 --> 00:38:03,310 and later stages, a quadruple or a six tuple phosphorylation. And 513 00:38:03,310 --> 00:38:08,890 so I'm excited about our platform being able to help us untangle, 514 00:38:09,130 --> 00:38:14,170 pun intended, all of this complexity of the variation in tau 515 00:38:14,490 --> 00:38:19,970 to really understand the progression of the disease and alongside 516 00:38:19,970 --> 00:38:25,770 that, understand how different therapeutics might abrogate that 517 00:38:25,770 --> 00:38:26,410 progression. 518 00:38:27,370 --> 00:38:32,930 Yeah, let me add to the work that we just have recently published 519 00:38:32,930 --> 00:38:37,470 on, on tau proteoform. So we essentially showed that we could 520 00:38:37,470 --> 00:38:41,710 develop an assay probing for about seven different phosphorylation 521 00:38:41,710 --> 00:38:45,190 sites. In addition, we directly probe for three different 522 00:38:45,190 --> 00:38:50,750 isoforms, obviously concluding from the measurements the different 523 00:38:51,230 --> 00:38:55,390 or six different types of isoforms. And then we applied that 524 00:38:56,030 --> 00:39:02,110 assay to a variety of different tissues. Maybe I'll just 525 00:39:02,110 --> 00:39:05,310 talk a little bit about one of them, which is the organoids, the 526 00:39:05,310 --> 00:39:10,310 cortical organoids. These are little mini brains, call them little 527 00:39:10,310 --> 00:39:15,910 brains, that are basically derived from IPSC cells. Those cells, 528 00:39:15,910 --> 00:39:20,790 IPSC cells, come from actual patients and so they contain mutants. 529 00:39:21,350 --> 00:39:27,150 In this case, those mutants are known to cause early frontotemporal 530 00:39:27,150 --> 00:39:31,190 dementia. And then we also had access to their isogenic controls. 531 00:39:31,350 --> 00:39:35,750 In this case, the CRISPR technology was used to remove those 532 00:39:35,750 --> 00:39:45,230 mutants and restore the natural sequence of tau. And then 533 00:39:45,230 --> 00:39:50,870 we compared or we simply analyzed those cell lines, those 534 00:39:51,030 --> 00:39:55,840 organoids, three dimensional cell cultures and compare them. The 535 00:39:55,840 --> 00:40:01,600 first insight that we actually had was that in theory, we could 536 00:40:01,600 --> 00:40:07,280 detect over 700 proteoforms with this particular assay. But in 537 00:40:07,280 --> 00:40:13,880 fact, what we see is that in mutant organoids, we see about 63 538 00:40:13,880 --> 00:40:20,120 proteforms. In the wild type, we see about 52 proteoforms. Clearly, 539 00:40:20,120 --> 00:40:23,990 not all the proteforms are theoretically possible, are actually 540 00:40:24,230 --> 00:40:29,270 found in those organoids. And so I think that's an important takeaway 541 00:40:29,510 --> 00:40:35,590 that when it comes to the combinatorial space that nature keeps 542 00:40:35,590 --> 00:40:40,590 ready, we only observe a small portion of it. And we could clearly 543 00:40:40,590 --> 00:40:44,790 quantify and compare those across those different organoids. 544 00:40:46,390 --> 00:40:49,350 When we looked at the mutants, what was actually very surprising 545 00:40:49,350 --> 00:40:54,510 there is that some of the mutants are known to express the 546 00:40:54,590 --> 00:41:00,310 longer form of tau, so the 4R tau at a higher percentage than the 547 00:41:00,310 --> 00:41:05,110 3R tau. So typically, those two forms of tau are balanced in 548 00:41:05,110 --> 00:41:09,310 the human brain, but in the case of this mutant, they're actually 549 00:41:09,310 --> 00:41:13,910 shifted towards the 4R. So there's more 4R Tau forms. What we 550 00:41:13,910 --> 00:41:17,390 could actually observe as those organoids grew and matured, 551 00:41:18,840 --> 00:41:23,040 we could actually see those longer forms of tau evolve and become 552 00:41:23,040 --> 00:41:26,960 more abundant. And that was very important for us to see, because 553 00:41:26,960 --> 00:41:30,680 I think that has been demonstrated using traditional Western 554 00:41:30,680 --> 00:41:35,480 blotting techniques. And the fact that we can very well recapitulate 555 00:41:35,480 --> 00:41:41,240 this particular biology was really very insightful. I think the 556 00:41:41,240 --> 00:41:46,130 other part that was interesting to us is that in those 557 00:41:46,130 --> 00:41:50,890 organoids, we see a lot of phosphorylation events that are more 558 00:41:50,890 --> 00:41:55,850 associated with the fatal state of cells. And so apparently 559 00:41:55,850 --> 00:42:01,090 what happens in fatal development, tau is being used at 560 00:42:01,090 --> 00:42:06,090 a highly phosphorylated state to really drive the growth of neurons 561 00:42:06,570 --> 00:42:11,600 within a developing brain. And so These organoids, these 3D organoids, 562 00:42:11,910 --> 00:42:16,150 perfectly recapitulate these particular developmental aspects 563 00:42:16,470 --> 00:42:21,990 of brain development. And so it was exciting to see that we actually 564 00:42:21,990 --> 00:42:26,550 can measure them and we could actually pinpoint those combinations 565 00:42:26,950 --> 00:42:32,070 of phosphorylation events that are critical for these development 566 00:42:32,310 --> 00:42:32,870 efforts. 567 00:42:34,470 --> 00:42:37,270 I think that's such a. Such an important point that you're raising, 568 00:42:37,890 --> 00:42:43,250 Andreas, which is that developing model systems to both 569 00:42:43,410 --> 00:42:48,690 test and discover the next generation of drugs and model systems 570 00:42:48,690 --> 00:42:53,410 that help us understand where the next biomarker might come from 571 00:42:54,210 --> 00:42:57,850 is incredibly challenging. There's a statement which is all 572 00:42:57,850 --> 00:43:03,450 models are wrong. Some models are useful. And so one of the areas 573 00:43:03,450 --> 00:43:08,460 where I'm really hoping that we can use the tau proteform assay 574 00:43:08,460 --> 00:43:14,140 to drive a step change is to understand where different models 575 00:43:14,860 --> 00:43:19,820 best describe the progression of the disease, and accordingly, 576 00:43:19,820 --> 00:43:23,500 which ones are altered by different therapeutics. I think that's 577 00:43:23,500 --> 00:43:28,060 a huge opportunity for the assay to give a little bit more color 578 00:43:28,060 --> 00:43:31,180 beyond the gross phenotype of just cell death. 579 00:43:33,050 --> 00:43:36,770 Yeah. And maybe one of the other areas that was surprising for 580 00:43:36,770 --> 00:43:42,770 me to see that in the end, the assay sensitivity was not the limiting 581 00:43:42,770 --> 00:43:46,410 factor. So it was really the biology that limited the number of 582 00:43:46,410 --> 00:43:51,410 protoforms that were observable. And I think that speaks 583 00:43:51,410 --> 00:43:55,010 for the robustness of the assay and the fact that we have the 584 00:43:55,010 --> 00:44:00,010 potential to measure many Many more. How proteforms. As we look 585 00:44:00,010 --> 00:44:05,890 into many more tissues in understanding either the developmental 586 00:44:05,890 --> 00:44:11,650 aspects of organoids or as you say, how do we utilize these model 587 00:44:11,650 --> 00:44:13,850 systems for drug development efforts? 588 00:44:15,210 --> 00:44:20,730 Well, I'm very, very excited about the potential impacts of proteoform 589 00:44:20,730 --> 00:44:25,210 focused studies and folks who are interested in learning more about 590 00:44:25,210 --> 00:44:28,890 Nautilus's platform and the ability to measure Tau proteforms, 591 00:44:29,210 --> 00:44:34,250 I recommend you check out our preprint at the link below and please 592 00:44:34,250 --> 00:44:36,090 do let us know what you think. 593 00:44:37,130 --> 00:44:41,170 I want to make sure that we also thank our collaborators at the 594 00:44:41,170 --> 00:44:45,410 Neural Stem Cell Institute in Albany. They put a lot of care and 595 00:44:45,410 --> 00:44:50,730 effort in growing those 3D cell cultures and provided us with, 596 00:44:51,410 --> 00:44:55,810 you know, organoids from many different patients and different 597 00:44:55,970 --> 00:44:58,290 ages. So thank you for their efforts. 598 00:44:59,090 --> 00:45:03,250 Yeah, they really have have built a tremendous model system and 599 00:45:03,490 --> 00:45:10,890 done such diligent work in, in both the creation and of that model 600 00:45:10,890 --> 00:45:14,290 system and also in ensuring that it's available to the broader 601 00:45:14,290 --> 00:45:18,130 community. Well, that's all the time we have to have today. Before 602 00:45:18,130 --> 00:45:23,950 we go, thank you all again for submitting your fantastic questions. 603 00:45:23,950 --> 00:45:28,030 I'm hoping we can do this kind of thing relatively regularly. So 604 00:45:28,030 --> 00:45:31,310 keep submitting your questions in the comments on social media and 605 00:45:31,310 --> 00:45:37,710 by emailing us translating ProteomicsNodilus bio. And as a reminder, 606 00:45:37,710 --> 00:45:41,510 I'll be answering many more questions about the Nautilus proteome 607 00:45:41,510 --> 00:45:46,530 analysis platform in a separate video on the Nautilus YouTube 608 00:45:46,530 --> 00:45:50,530 channel. We'll get that video to you as soon as possible and in 609 00:45:50,530 --> 00:45:53,890 the meantime, be sure to check out all the Nautilus focused resources 610 00:45:53,890 --> 00:45:58,090 on our website at Nautilus Bio. Thanks again for joining us 611 00:45:58,090 --> 00:46:02,170 on this episode of Translating Proteomics. I look forward to seeing 612 00:46:02,170 --> 00:46:03,650 you again on our next episode. 613 00:46:07,010 --> 00:46:10,800 We hope you enjoyed the Translating Proteomics podcast brought 614 00:46:10,800 --> 00:46:14,760 to you by Nautilus Biotechnology. To contact us or for 615 00:46:14,760 --> 00:46:19,160 further information, Please email translating ProteomicsNautilus 616 00:46:19,240 --> 00:46:19,720 bio.